natgillin/translations-raw huggingface dataset:
When the addition was complete, the resulting yellow solution was stirred for a further ten minutes before pouring on to a rapidly stirred mixture of sodium carbonate (15 g) in water (90 ml) and crushed ice (90 g). 
Nakon završetka dodavanja, rezultirajuća žuta otopina se miješa tijekom daljnjih deset minuta prije ulijevanja u snažno miješanu smjesu natrij karbonata (15 g) u vodi (90 ml) i smrvljenog leda (90 g).
5 shows the SDS-PAGE analysis of load and elution fractions from MEP HYPERCEL® column loaded with r-hIL6-IL6R chimera in FBS containing crude harvest. 
Slika 5 prikazuje SDS-PAGE analizu frakcija punjenja 1 ispiranja na koloni MEP HyperCel napunjenoj sa himernim <T- hIL6-IL6R u sirovom materijalu koji je sadržavao FBS.
In a further preferred embodiment the composition according to the invention is such that the average particle size of the donepezil hydrochloride is 5 to 300 µm, preferably 10 to 150 µm. 
U daljnjem poželjnom vidu, pripravak prema izumu je takav da je prosječna veličina čestice donepezil hidroklorida 5 do 300 um, poželjnije 10 do 150 um.
R3c is independently selected from H, CHF2, CD3, CH3, SO2CH3, phenyl optionally substituted with R6, and 5- to 6-membered heterocyclyl optionally substituted with R6, 5- to 6-membered heteroaryl optionally substituted with R6; 
c je nezavisno odabrano od H, CHF2, CD3, CH3, SO2CH3, fenil po izboru supstituiran sa R6, i 5- do 6-očlani heterociklil po izboru supstituiran sa R6, 5- do 6-očlani heteroaril po izboru supstituiran sa R6;
wherein the shRNA molecule is expressed in the mammalian cell in an amount sufficient to attenuate expression of the target gene in a sequence specific manner, whereby expression of the target gene is inhibited. 
Ekspresijski vektor prema patentnom zahtjevu 8, naznačen time, da se koristi za snižavanje ekspresije ciljnog gena u stanici sisavca.
The method of claim 15, wherein said adsorbent is activated carbon. The method of any one of claims 1 to 14, further comprising passing the reaction mixture through an inline filter cartridge comprising a filter medium to obtain a clear filtrate solution of the reaction mixture prior to said precipitating. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time da nadalje sadrži prolaz puferske otopine monomernog kompleksa platina pirofosfata kroz protočni (inline) filter koji sadrži medij za filtriranje radi uklanjanja nerastopljenih krutina kako bi se dobila bistra otopina filtrata prije spomenute rekristalizacije.
A composition comprising compound 10 having the structure: 
Kompozicija koja sadrži: 1) spoj 10
The compound as claimed in claim 1 wherein the compound is or a N-oxide, addition salt, quaternary amine, or metal complex thereof. 
Spoj kako je zatraženo u zahtjevu 1 naznačen time da je spoj [image] ili N-oksid, adicijska sol, kvaterni amin, ili njihov metalni kompleks.
an amino acid sequence encoded by a nucleic acid sequence as shown in SEQ ID NOs. 
(b) -aminokiselinski slijed kojeg kodira nukleinskokiselinski slijed kao što je prikazan u SEQ ID NO.
FIG. 1 provides a plan view of a hand-held transmitter used in the present invention. 
Slika 1 prikazuje planarni pogled na ručni odašiljač koji se koristi u opisanom izumu.
CRL-9096] when expressed therein; and/or it has an amount of G0 structures on the total carbohydrate structures or on the carbohydrate structures at one particular glycosylation site of the protein molecule of said protein molecules in said protein molecule composition which is at least 5% lower compared to the same amount of protein molecules in at least one protein molecule composition of the same protein molecule isolated from CHOdhfr- [ATCC No. 
CRL-9096 (CHOdhfr-) kada se tamo eksprimira; i/ili - ima količinu G2 struktura na ukupnim ugljikohidratnim strukturama ili na ugljikohidratnim strukturama na nekom određenom mjestu glikoziliranja u molekuli protutijela kod navedenih molekula protutijela u navedenom pripravku s molekulom protutijela koja je najmanje 5% veća u usporedbi s istom količinom molekula protutijela u pripravku s najmanje jednom molekulom protutijela za istu molekula protutijela izoliranu iz ATCC No.
A method according to claim 1 wherein the method of contacting is by administration of the compound from a medicament dispenser selected from a reservoir dry powder inhaler, a multi-dose dry powder inhaler or a metered dose inhaler. 
Upotreba u skladu s patentnim zahtjevom 11, naznačena time što se primjenu provodi uz pomoć dozatora za medikamente, kojeg se bira između inhalatora sa spremnikom sa suhim prahom, višedoznog inhalatora sa suhim prahom ili inhalatora za odmjerene doze.
The designation of substituent X as chloro, fluoro or bromo means that both substituents X have the same meanings. 
NN CH, naznačen time da R, je difluorometil ili trifluorometil i X je kloro, fluoro ili bromo; i
The use according to claim 33, wherein the the anti-a2 integrin antibody inhibits the binding of a2B1 integrin to collagen and is not a ligand mimetic. 
Uporaba prema zahtjevu 33, gdje anti-a2 integrin protutijelo inhibira vezanje a2B1 integrina za kolagen i ne oponaša ligand.
An anti-IL-6 antibody according to claim 1, comprising a VL chain and a VH chain, respectively, comprising the amino acid sequences of SEQ ID NO:2 and SEQ ID NO:3; SEQ ID NO:2 and SEQ ID NO:18; SEQ ID NO:2 and SEQ ID NO:19; SEQ ID NO:20 and SEQ ID NO:3; SEQ ID NO:20 and SEQ ID NO:18; or SEQ ID NO:20 and SEQ ID NO:19, or an antibody comprising a VL chain and a VH chain, respectively, comprising amino acid sequences having at least 90% or greater homology thereto. 
Anti-IL6 protutijelo ili njegov fragment u skladu s patentnim zahtjevom 1, sadrži VL lanac i VH lanac, redom, koji ima aminokiselinske sljedove SEQ ID NO:2 i SEQ ID NO:3; SEQ ID NO:2 i SEQ ID NO:18; SEQ ID NO:2 i SEQ ID NO:19; SEQ ID NO:20 i SEQ ID NO:3; SEQ ID NO:20 i SEQ ID NO:18; ili SEQ ID NO:20 i SEQ ID NO:19, ili protutijelo ili njegov fragment sadrži VL lanac i VH lanac, redom, koji ima aminokiselinske sljedove koji k tome imaju najmanje 90% ili više homologije.
The compound of claim 1, wherein the compound of Formula I is 5-fluoro-4-imino-3-methyl-3,4-dihydropyrimidin-2(1 H)-one. 
Spoj prema patentnom zahtjevu 1, naznačen time, da spoj formule I jest 5-flor-4-imino-3-metil-3,4-dihidropirimidin-2(1H)-on.
4 presents the cut-out in the bottom wall 26, which reflects the cut-out situated in the upper part of the front wall 7 or top wall 25 and facilitates the process of mass production of the front wall 7 . 
S1. 4 prikazuje otvor na donjem zidu 26 koji reflektira otvor na gornjem dijelu prednjeg zida 7 ili gornjeg zida 25 i olakšava proces masovne proizvodnje prednjeg zida 7.
A composition according to claim 1, wherein X is N. 
Pripravak u skladu sa zahtjevom 1, naznačen time, da X je N.
The uplink synchronous status is sustained until the timer expires. According to one embodiment of the present invention, a mobile station device transmits a random access preamble to a base station device and resets a timer managing an uplink synchronous status based on reception of the synchronization timing deviation information included in a random access response that the base station device transmits in response to the transmitted random access preamble, wherein, in the uplink synchronous status, the mobile station device does not perform to reset the timer based on reception of synchronization timing deviation information included in a random access response which is a response to a random access preamble whose preamble ID is randomly selected by the mobile station device. 
Uređaj mobilne stanice (50) prema zahtjevu 1, naznačen time da je uređaj mobilne stanice (50) nadalje prilagođen da upravlja sinkronim statusom uzlazne veze korištenjem vremenskog brojača tako da se sinkroni status uzlazne veze održava sve dok istekne vremenski brojač nakon što se vremenski brojač resetira, te pri čemu korak odbacivanja sadrži, u sinkronom statusu uzlazne veze, ne resetiranje vremenskog brojača na osnovi informacije o odstupanju vremena sadržane u primljenom odgovoru slučajnog pristupa (S02).
See example, S.M. Berge, et al., "Pharmaceutical Salts," J. Pharm. 
Vidjeti primjer, S. M. Berge i suradnici, "Pharmaceutical salts," J. Pharm.
The method of claim 20, wherein said virus removal step is nanofiltration. The method of claim 18, wherein said at least one polishing step comprises subjecting said crude antibody composition to at least one ionic exchange chromatography (IEX) step. 
Postupak u skladu s patentnim zahtjevom 11, naznačen time što se navedeni najmanje jedan korak finog pročišćavanja sastoji u podvrgavanju navedenog sirovog pripravka protutijela najmanje jednom koraku ionskoizmjenjivačke kromatografije (IEX).
when R6 and R7 are attached to the same carbon atom, they optionally form a moiety (A) described above, wherein Ra and Rb are independently hydrogen, or (C1-C4) alkyl, or Ra and Rb taken together with said carbon atom optionally form a 3-8-membered ring; or a pharmaceutically acceptable salt thereof; or an optical isomer thereof; or a mixture of optical isomers. 
(Ci-C7)alkil, (Cy-Cz)haloalkil, aril, ili -NH; ili kada su Rg 1 R; priključeni na isti atom ugljika,oni zajedno s tim ugljikovim atomom opcijski tvore 3-8-člani prsten; ili njegova farmaceutski prihvatljiva sol; ili njegov optički izomer; ili mješavina optičkih izomera; HR P20130797 TI ili spoj odabran iz skupine koju čine:
The methods used in the art imply the use of costly Palladium catalysts. 
Postupci korišteni u struci ukazuju na uporabu skupog paladijskog katalizatora.
The flask was evacuated and filled with nitrogen 4 times then anhydrous 1,4-dioxane (17.5 ml, 7vol) was added. 
Tikvicu se evakuira, 4 x napuni dušikom, te se doda bezvodni 1,4-dioksan (17,5 ml, 7 volumnih udjela).
The antibody of claim 1 which is capable of binding to CLDN6 associated with the surface of a cell that expresses CLDN6 and is not substantially capable of binding to CLDN9 associated with the surface of a cell that expresses CLDN9. 
Antitijelo suglasno zahtjevu 1, koje je sposobno da se veže za CLDNG6 asociran na membrani stanice koja eksprimira CLDNS6 i koje u biti nije sposobno da se veže za CLDNO.
Figure 2 shows a method, by which the data sheet is produced and Figure 3 shows the structure of a completed data sheet. 
Slika 2 prikazuje postupak pomoću kojega se izrađuje list za podatke, a slika 3 prikazuje strukturu kompletiranog lista za podatke.
7-t-Butoxyiminomethyl-camptothecin is the most preferred combination partner (a). 
Farmaceutski oblik koji sadrži (a) 7-t-butoksiiminometilkamptotecin; i (b) karboplatin.
Acid addition salts of the compounds of formula I, due to their increased water solubility over the corresponding base form, are more suitable in the preparation of aqueous compositions. 
Kisele adicijske soli spojeva formule I, zahvaljujući svojoj povećanoj topljivosti u vodi u odnosu na odgovarajući bazični oblik, pogodniji su za pripravu vodenih pripravaka.
A combination of GPR119 agonist and DPP-IV inhibitor in accordance with the present invention is useful in treating or preventing diabetes and conditions related thereto. 
Pripravak u skladu sa zahtjevom 1, naznačen time, da GPR119 agonist je agonist humanog GPR119, te DPP-IV inhibitor je inhibitor humanog DPP-IV.
subjects having a serum triacylglycerol level of at least 150 mg/dL [at least 200 mg/dL; at least 500 mg/dL], wherein said triacylglycerol level is determined after fasting for at least 8 hours; 
(iv) subjekti koji imaju razinu triacilglicerola u serumu od barem 150 mg/dI., pri čemu se navedena razina triacilglicerola određuje poslije najmanje 8 sati natašte.
The pharmaceutical formulation of claim 9, wherein said formulation is in the form of a tablet, a pill, powder, a capsule, syrup, an emulsion or a microemulsion. 
Farmaceutska formulacija u skladu s patentnim zahtjevom 19, pri čemu je navedena formulacija u obliku tablete, pilule, praška, kapsule, sirupa, emulzije ili mikroemulzije.
% of at least one calcium carbonate-comprising material and having a pH in the range of between 8.5 and 11, characterized in that the method involves the step of adding 2-((1-methylpropyl)amino)ethanol to the suspension in an amount, so that the pH of the suspension is increased by at least 0.3 pH units and, at the same time, the suspension conductivity change is not more than 100 µS/cm per pH unit, and characterized in that said 2-((1-methylpropyl)amino)ethanol is added to said suspension in an amount of from 500 to 15000 mg, per liter of the aqueous phase of said suspension. 
Postupak povećavanja pH vodene suspenzije koja sadrži 25 do 62 vol.% barem jednog materijala s kalcijevim karbonatom i ima pH između 8,5 1 11, naznačen time da postupak uključuje korak dodavanja 2-((1- metilpropil)amino)etanola u suspenziju u količini za povećanje pH otopine za najmanje 0,3 pH jedinice, pri čemu promjena vodljivosti otopine nije veća od 100 uS/em po jedinici pH, naznačen time da je navedeni 2-((1- metilpropil)amino)etanol dodan u navedenu otopinu u količini od 500 do 15000 mg, po litri vodene faze navedene otopine.
Four slivers of cotton were tightly braided together with cotton string to form a rope with a diameter of about 0.4 in. 
Četiri pamučna rukavca su čvrsto zajednički stisnuta sa pamučnom niti tako da se formira konop promjera oko 10.2 mm.
In yet another embodiment, the average particle size (D50), as measured by laser diffraction, was determined to be controllable in the range of 7-13 microns. 
Prekursor materijal prema zahtjevu 4, u kome prekursor materijal ima prosječnu veličinu čestica (D50) u rasponu od 7 do 13 mikrona.
a source of injectable fluids in fluid communication with said pump, wherein the needle is in fluid communication with the pump, the needle being configured to inject the injectable fluids into a tissue disposed in the recessed area. 
Uređaj za minimalno invazivni tretman kože u skladu s patentnim zahtjevom 1, naznačen time, da je alat igla, (1001), uređaj dodatno obuhvaća: pumpu i izvor injekcijskih tekućina u fluidnoj vezi s navedenom crpkom, pri čemu je igla fluidno povezana s pumpom, igla je konfigurirana tako da se mogu uštrcavati tekućine za injektiranje u tkivo smješteno u udubljenom području.
solvent C which is selected from the group consisting of C1- C5 straight and branched alcohols and mixtures thereof, wherein solvent C is selected to provide lower solubility to epidaunorubicin hydrochloride than solvent B. 
Otapala C, koje je odabrano iz skupine, koja se sastoji od ravnolančanih i razgranjenih C1- do C5- alkohola i njihovih mješavina, pri čemu je otapalo C odgovarajuće odabrano, tako da 4'-epidaunorubicin-hidroklorid pri tome ima manju topljivost nego u otapalu B.
Process of any one of claims 9 to 11, wherein the amino protecting group R4 is FMOC and its removal in step b1) is performed with a secondary aliphatic amine in a polar aprotic solvent at a reaction temperature of 20°C to 50°C. 
Postupak prema bilo kojem od patentnih zahtjeva 9 do 11, naznačen time, da amino zaštitna skupina R4je FMOC i njezino uklanjanje u koraku b1) izvodi se sa sekundarnim alifatskim aminom u polarnom aprotičnom otapalu, pri reakcijskoj temperaturi od 20 °C do 50 °C.
incubating said partly AX-REED treated liquid in said chamber, whereby the direction of electric field is reversed at intervals; and 
VIII. inkubiranje navedene djelomično obrađene tekućine AX-REED u navedenoj komori, pri čemu se smjer električnog polja preokreće u intervalima;
each R1 linked to the carbon atoms at positions 3 and 4 of the piperidine ring is independently —ONO2; and R1 linked to the carbon atom at position 5 of the piperidine ring is H; 
svaki od R1 vezan na ugljikove atome u položajima 3 i 4 piperidinskog prstena je skupina donor dušikovog monoksida -ONO2; i R1 vezan na ugljikov atom u položaju 5 piperidinskog prstena je H (ovdje identificirani kao spojevi redom 5b1, 5b2 i 5b3);
A pharmaceutical composition according to claim 9, wherein the binder is one or more selected from the group comprising carbohydrates like celluloses their derivatives; starches; gums; polyvinylpyrrolidone, povidone, syrup, polyethylene oxide, polyacryl amide, poly-N-vinyl amide, sodium carboxymethyl cellulose, polyethylene glycol, gelatin, polyethylene oxide, poly propylene glycol, tragacanth, alginic acid and combinations thereof. 
Oralni farmaceutski pripravak s kontroliranim oslobađanjem u skladu sa zahtjevom 8, naznačen time da je vezivno sredstvo jedno ili više njih, odabranih između ugljikohidrata kao što su celuloze; škrobovi; gume; polivinil pirolidon, povidon, sirup, polietilen oksid, poliakril amid, poli-N-vinil amid, natrij karbosimetil celuloza, polietilen glikol, želatina, polietilen oksid, polipropilen glikol, tragakant, algmska kiselina ili kombinacije istih.
the foundation body (10) has a support structure (30) which separates the playing surface (11) from a base (2), characterized in that 
osnovno tijelo (10) ima nosivu strukturu (30), koja odvaja igraću površinu (11) od podnožja (2), naznačen time što -
Compounds in the present invention may be useful in treating memory impairment and cognitive disorders. 
Spojevi prikazanog izuma mogu koristiti u liječenju oslabljenog pamćenja i kognitivnih poremećaja.
The system according to claim 1, wherein the auxiliary opening opens upstream of most radially peripheral stage. 
Sustav sukladno jednom od prethodnih zahtjeva, pri čemu se pomoćni otvor (40c) otvara iznad najviše radijalno periferne faze.
a solid-state 13C NMR spectrum with signals at 112.3, 163.9, 168.8 ± 0.2 ppm; 
(b) "*C-NMR spektra čvrstog stanja, sa signalima na 112,3, 163,9, 168,8 + 0,2 ppm;
The formulation of claim 1, wherein the inner layer further comprises a base and the base is sodium hydroxide. 
Formulacija lijeka s odloženim otpuštanjem sukladno u jednom od prethodnih patentnih zahtjeva, naznačeno time, da je ta osnova natrij hidroksid.
micro air bubbles) and has a dielectric strength of 16.5 kV/mm; 
mikromjehurića zraka) i ima dielektričku čvrstoću od 16,5 kV/mm;
means for measuring the content of Staphylococcus bacteria; and means for calculating the chance according to the formula defined above. 
Sredstva za mjerenje sadržaja Staphylococcus bakterija, poželjno pri čemu navedena sredstva sadrže početnice 5'-GAGTAACACGTGGATAACCTACCTATAAGAC-3' 1 5'-GCATCGTTGCCTTGGTAAGCd.
a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO: 3 (huMov19 vHC) and a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 5 (huMov19 vLCv1.60). 
(ii) varijabilnu domenu teškog lanca koja sadrži aminokiselinski slijed SEQ ID NO: 3 (huMov19 vHC) 1 varijabilnu domenu lakog lanca koja sadrži aminokiselinski slijed SEQ ID NO: 5 (huMov19 vLCv1.60).
The elution is started with 3 L of a 1:1 mixture, and after that, the percentage of the polar solvent increased, first with 2 L of a 3:5 mixture, later with 2 L of a 1:2 mixture and finally eluted only with AcOEt. 
Ispiranje se započne s 3 L mješavine 1:1 i nakon toga se povećava postotak polarnog otapala, najprije s 2 L mješavine 3:5, a kasnije s 2 L mješavine 1:2 i konačno se ispire samo s AcOEt.
The liposome according to claim 1, characterized in that the said liposome comprises the following weight ratios of ingredients: 
Liposom prema zahtjevu 1, naznačen time što taj liposom sadrži sljedeće težinske omjere sastojaka:
The method of claim 23 wherein the seed is coated with the compound of claim 1 formulated as a composition comprising a film former or adhesive agent. 
Metoda iz Zahtjeva 23, naznačena time, što se sjeme oblaže spojem iz Zahtjeva 1 formuliranim u smjesu koja uključuje sredstvo za formiranje filma ili adhezivno sredstvo.
The system works with boats that have been built with electronic controls. 
Sustav radi za plovila koja imaju ugrađene elektronske upravljačke kontrole.
Het is a 5 membered heteroaryl ring, where the heteroaryl ring contains 1 to 4 heteroatoms selected from N, O and S as ring members and is optionally substituted with one or two groups selected from Y, OH, NH2, -C(O)NR102, and C1-4 alkyl optionally substituted with one or two Y; 
Het je 4-6-člani zasićeni heterociklični prsten, pri čemu heterociklični prsten sadrži 1 ili 2 heteroatoma odabranih od N, O i S kao članove prstena i supstituiran je s okso i izborno je dalje supstituiran s Y;
-NR2aCOR2b, wherein R2a, and R2b are independently selected from the group consisting of 
(9) -NRxCORx, gdje R2, i Ry su neovisno odabrani iz skupine koja sadrži (a) vodik, i
An intermediate silicone tie coat containing a vulcanizable silicon applied over and to the layer comprising a polar thermoplastic polymer (iii), 
(iv) silikonski vežući međupremaz, koji sadrži vulkanizabilni silikon kojeg se primjenjuje preko i na sloj koji sadrži polarni termoplastični polimer (iii);
X and X' are independently selected from O, S and N(H). 
X i X' su neovisno odabrani od O, S i N(H).
The process of claim 1, wherein the residuum hydrocarbon fraction (10) comprises at least one of petroleum atmospheric or vacuum residua, deasphalted oils, deasphalter pitch, hydrocracked atmospheric tower or vacuum tower bottom, straight run vacuum gas oil, hydrocracked vacuum gas oil, fluid catalytically cracked (FCC) slurry oils, vacuum gas oil from an ebullated bed process, shale-derived oils, coal-derived oils, bioderived crude oils, tar sands bitumen, tall oils, black oils. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da ostatak ugljikovodične frakcije (10) sadržava barem jedno od sljedećeg: naftni atmosferski ili vakuumski ostatak, deasfaltirana ulja, smola iz deasfaltara, ostaci s dna kolone atmosferskog krekiranja ili vakuumske kolone, plinska ulja izravne vakuumske destilacije, vakuumski hidrokrekirano plinsko ulje, maziva ulja dobivena katalitičkim krekiranjem u fluidnom stanju (FCC), plinsko ulje dobiveno postupkom vakuumske destilacije u vrijućem sloju, ulja iz škriljevca, ulja dobivena iz ugljena, sirovih ulja bio podrijetla, bitumen iz naftnog pijeska, ulja iz (pulpe) drveta, crna ulja.
The base station apparatus according to claim 1, wherein the remaining bits are MSBs Most Significant Bits, of the resource allocation information and the specified value is zero. 
Uređaj za prijenos prema zahtjevu 1 ili 2, naznačen time da su preostali bi(ovi) MSB-ovi, NajBitniji Bitovi, podatka o dodjeli resursa, a definirana vrijednost je nula.
A sustained release aminopyridine composition for use in a method of treating multiple sclerosis, wherein said composition is administered twice daily in a dose of 10 milligrams or less of aminopyridine. 
Kompozicija aminopiridina sa produženim oslobađanjem za poboljšanje mišićnog tonusa donjih ekstremiteta kod pacijenta sa multiplom sklerozom, naznačena time što je navedena kompozicija za primjenu kao tretman stabilnom dozom dva puta na dan u terapeutskoj dozi od 15 miligrama ili manje aminopiridina.
deformylating the compound of Formula LXV to give the compound of Formula LXVI, wherein 
Formula LX m. deformilaciju spoja Formule LXV, čime se dobiva spoj Formule LXVI:
The compound according to claim 1 or the pharmaceutical composition of claim 2 for use in treating a disease and/or disorder of the eye. 
Spoj ili farmaceutski pripravak za uporabu prema zahtjevu 4, naznačen time da je za uporabu kod liječenja bolesti i/ili poremećaja oka.
In this instance, the martensitic transformation is preferably triggered simultaneously with or after the curing is initiated, but before the curing is completed. 
Na taj način je martenzitska transformacija preferirano potaknuta istovremeno ili nakon početka očvršćivanja, ali prije završetka očvršćivanja.
A composition according to claims 1-2, wherein said tamarind extract has a titrated polysaccharide xyloglucan content of at least 30% by weight, preferably at least 75% by weight. 
Pripravak za upotrebu prema patentnom zahtjevu 1, naznačeno time da rečeni ekstrakt tamarinda ima titriran sadržaj polisaharid-ksiloglukana od najmanje 75% po masi.
It is further thought that buprenorphine binds with high affinity to µ and k1 receptors, and, with lower affinity, to δ receptors. 
Dalje se mislilo da se buprenorfin veže visokim afinitetom za u i Ki receptore, a nižim afinitetom za & receptore.